Content about Bristol-Myers Squibb

February 18, 2011

A whole slew of drugs will lose patent protection this year, opening up opportunities for generic drug makers to market their own versions. Most notable among these is Pfizer’s cholesterol-
lowering drug Lipitor (atorvastatin), the world’s top-selling drug, with U.S. sales of $7 billion during the 12 months ended September 2010, according to IMS Health.


February 17, 2011

The Food and Drug Administration has approved a psychiatric drug for treating bipolar disorder when used in combination with one of two other drugs.

PRINCETON, N.J. — The Food and Drug Administration has approved a psychiatric drug for treating bipolar disorder when used in combination with one of two other drugs.

The FDA approved Abilify (aripiprazole), made by Bristol-Myers Squibb and Otsuka Pharmaceutical, as an adjunct to lithium or valproate for maintenance treatment of bipolar I disorder.

February 14, 2011

An investigational drug made by Bristol-Myers Squibb works better than aspirin in reducing the risk of complications in certain patients with heart rhythm problems, according to results of a late-stage clinical trial published in the New England Journal of Medicine.

NEW YORK — An investigational drug made by Bristol-Myers Squibb works better than aspirin in reducing the risk of complications in certain patients with heart rhythm problems, according to results of a late-stage clinical trial published in the New England Journal of Medicine.

Bristol said results of the phase-3 study comparing apixaban with aspirin showed that in patients with atrial fibrillation who were not suited to take the drug warfarin, apixaban was more effective than aspirin in reducing stroke and systemic embolism.

January 7, 2011

A new oral treatment for Type 2 diabetes hit the shelves Friday.

PRINCETON, N.J. — A new oral treatment for Type 2 diabetes hit the shelves Friday.

Bristol-Myers Squibb and AstraZeneca announced the availability of Kombiglyze XR (saxagliptin and metformin hydrochloride), which the companies called the only once-daily treatment for diabetes that combined metformin with a DPP-4 inhibitor, the drug class to which saxagliptin belongs.

The drug is designed for use alongside diet and exercise to improve glycemic control in adults with Type 2 diabetes.

December 21, 2010

Bristol-Myers Squibb has signed a definitive licensing pact with Oncolys BioPharma, a privately held Japanese biotech company, that will give it control of a promising new HIV treatment.

NEW YORK and TOKYO — Bristol-Myers Squibb has signed a definitive licensing pact with Oncolys BioPharma, a privately held Japanese biotech company, that will give it control of a promising new HIV treatment.

December 8, 2010

Chemotherapy drugs made by Johnson & Johnson and Merck will become the standard second-line treatment for ovarian cancer within the decade, replacing a treatment made by Bristol-Myers Squibb and generic versions, according to a new report by market research firm Decision Resources.

BURLINGTON, Mass. — Chemotherapy drugs made by Johnson & Johnson and Merck will become the standard second-line treatment for ovarian cancer within the decade, replacing a treatment made by Bristol-Myers Squibb and generic versions, according to a new report by market research firm Decision Resources.

December 7, 2010

The Food and Drug Administration has accepted for review a supplemental approval application for an arthritis drug made by Bristol-Myers Squibb, the drug maker said Monday.

PRINCETON, N.J. — The Food and Drug Administration has accepted for review a supplemental approval application for an arthritis drug made by Bristol-Myers Squibb, the drug maker said Monday.

Bristol is seeking approval for Orencia (abatacept) injected into the skin as a treatment for adults with moderate to severe rheumatoid arthritis. The drug already is approved for intravenous injection.

November 15, 2010

The U.S. District Court for the District of Delaware has upheld a patent held by...

INDIANAPOLIS — The U.S. District Court for the District of Delaware has upheld a patent held by Indianapolis-based drug maker Eli Lilly covering a chemotherapy drug, Lilly said Monday.

 

The case concerns a patent covering Alimta (pemetrexed) that expires in July 2016 and generic drug maker Teva Pharmaceutical Industries’ challenge to it.

 

 

November 14, 2010

Look for a big surge in brand-to-generic drug switches at the pharmacy counter over the...

NEW YORK — Look for a big surge in brand-to-generic drug switches at the pharmacy counter over the next year.

November 10, 2010

A drug maker's philanthropic arm announced its commitment to fight Type 2 diabetes in the...

November 7, 2010

The Food and Drug Administration approved the first and only once-a-day metformin extended-release plus dipeptidyl...

November 7, 2010

Patients with rheumatoid arthritis derive about as much benefit from a weekly injection of a...

NEW YORK Patients with rheumatoid arthritis derive about as much benefit from a weekly injection of a biotech drug made by Bristol-Myers Squibb for the disease as they do from receiving it via IV on a monthly basis, according to late-stage clinical trial data released Monday.

October 27, 2010

The Food and Drug Administration has approved a new usage for a blood cancer drug,...

October 4, 2010

The Food and Drug Administration has approved a generic drug for HIV made by a...

PITTSBURGH The Food and Drug Administration has approved a generic drug for HIV made by a subsidiary of Mylan under a program that supplies drugs to people living with HIV in developing countries, Mylan said Tuesday.

 

September 27, 2010

The Hart-Scott-Rodino waiting period for Bristol-Myers Squibb’s acquisition of Seattle-based biotech company ZymoGenetics has expired,...

NEW YORK The Hart-Scott-Rodino waiting period for Bristol-Myers Squibb’s acquisition of Seattle-based biotech company ZymoGenetics has expired, enabling Bristol’s acquisition to go through, the drug maker said Tuesday.

 

The drug maker announced the deal to acquire ZymoGenetics for $885 million, or $9.75 per share, earlier this month.

 

 

September 23, 2010

An investigational diabetes drug works as well as a generic already on the market, according...

STOCKHOLM An investigational diabetes drug works as well as a generic already on the market, according to results of a late-stage clinical trial announced Friday by AstraZeneca and Bristol-Myers Squibb.

 

September 21, 2010

Abbott on Wednesday initiated a proactive, voluntary recall of certain Similac powder infant formulas in...

ABBOTT PARK, Ill. Abbott on Wednesday initiated a proactive, voluntary recall of certain Similac powder infant formulas in the United States, Puerto Rico, Guam and some countries in the Caribbean following an internal quality review, which detected the remote possibility of the presence of a small common beetle in the product, produced in one production area in a single manufacturing facility.

September 12, 2010

An investigational treatment for HIV by Gilead Sciences that combines four drugs in one tablet...

FOSTER CITY, Calif. An investigational treatment for HIV by Gilead Sciences that combines four drugs in one tablet works as well as a drug already on the market, Gilead said Monday.

 

September 9, 2010

Bristol-Myers Squibb formally has begun its tender offer for biotech company ZymoGenetics, the drug maker...

NEW YORK Bristol-Myers Squibb formally has begun its tender offer for biotech company ZymoGenetics, the drug maker said Friday.

 

Bristol-Myers Squibb announced its intent to acquire the Seattle-based company earlier this week for $885 million, or $9.75 per share.

 

 

September 7, 2010

Bristol-Myers Squibb will acquire Seattle-based biotech ZymoGenetics, Bristol said Wednesday....

SEATTLE Bristol-Myers Squibb will acquire Seattle-based biotech ZymoGenetics, Bristol said Wednesday.

 

The New York-based drug maker will acquire ZymoGenetics for $885 million, or $9.75 per share. The boards of both companies approved the deal unanimously.

 

 

The buyout gives Bristol ownership of Recothrom, used to control bleeding during surgical procedures, pegylated-interferon lambda, an investigational treatment for hepatitis C in mid-stage clinical trials, and IL-21, a treatment for melanoma also in mid-stage trials.

August 17, 2010

The Food and Drug Administration has agreed to expedite review of an investigational treatment for...

August 10, 2010

The drug market for unipolar depression will get smaller over the next decade due to...

July 21, 2010

An investigational treatment for HIV made by Johnson & Johnson subsidiary Tibotec Pharmaceuticals works as...

June 21, 2010

Cases of the potentially deadly skin cancer melanoma are expected to almost double before the...

NEW YORK Cases of the potentially deadly skin cancer melanoma are expected to almost double before the end of the decade, according to a new report by research firm Datamonitor.

 

Research by the company indicated that cases of melanoma could go from the 138,000 new cases expected this year to 227,000 by 2019.

 

 

June 6, 2010

An investigational drug for skin cancer that had spread to other parts of the body...